ArticleFrontiers in pain research (Lausanne, Switzerland)2026
Beyond traditional treatments: vagal nerve stimulation for painful temporomandibular disorders.
Article in Frontiers in pain research (Lausanne, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Chronic temporomandibular disorders (TMD) can progress to refractory chronic pain in a subset of patients, for whom standard multimodal treatments often provide limited relief. Emerging neuromodulation therapies-particularly non-invasive vagal nerve stimulation (nVNS)-suggest a potential non-pharmacologic adjunct within multimodal strategies for managing persistent symptoms. This case series explores the use of non-invasive nVNS in conjunction with a multimodal treatment strategy for managing refractory pain in patients with chronic TMD. Methods: A retrospective review at the University of Minnesota TMD, Orofacial Pain and Dental Sleep Medicine Clinic, evaluated patients with chronic TMD pain treated with a multimodal treatment plan which included GammaCore nVNS device, by comparing their baseline data to outcomes at their most recent follow-up. Results: Three patients (mean age 44.3 ± 23.3 years) with refractory TMD pain were identified as having received nVNS therapy using the GammaCore device. Treatment duration ranged from 4.6 to 18.2 months and was self-administered three to four times per day. All three patients reported improvements in pain intensity, pain-related disability, and psychosocial functioning, in the context of a multimodal treatment plan that included nVNS. Discussion: Our limited clinical experience observed improvements across multiple domains relevant to patients with chronic TMD in the context of a multimodal treatment plan that included nVNS.IRB approval status: Approved STUDY00024420.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.